{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T05:54:10Z","timestamp":1781589250801,"version":"3.54.5"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study aimed to comprehensively analyze the adverse events associated with neuraminidase inhibitor (NAI) use in pregnant women in real-world clinical settings, providing a valuable reference for the management of anti-influenza treatment in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study extracted data from the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database, spanning from the first quarter of 2004 to the third quarter of 2025. Signal detection was performed using the reporting odds ratio (ROR) and Bayesian confidence propagation neural network (BCPNN) methods. Adverse events (AEs) were classified according to the system organ class (SOC) in the Medical Dictionary for Regulatory Activities (MedDRA) version 27.0.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From Q1 2004 to Q3 2025, a total of 3,687 ADE reports were retrieved in this study, including 3,211 reports for oseltamivir, 471 reports for zanamivir, and 5 reports for peramivir. For oseltamivir, significant AEs at SOCs were injury, poisoning, and procedural complications; pregnancy, puerperium, and perinatal conditions; and general disorders and administration site conditions. The five strongest AE signals were proctitis, infantile acne, congenital intestinal obstruction, no adverse event, and placental necrosis. For zanamivir, significant AEs at SOCs were injury, poisoning, and procedural complications; pregnancy, puerperium, and perinatal conditions; and respiratory, thoracic, and mediastinal disorders. The five strongest AE signals were delivery, bronchospasm, pneumothorax, exposure during pregnancy, and product quality issue.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The study findings align with current guidelines recommending neuraminidase inhibitors as the primary antiviral treatment of pregnant women with influenza. Our study may offer valuable evidence to support the clinical use of neuraminidase inhibitors, particularly in identifying adverse events and ensuring their safe administration in women during pregnancy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1821866","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T05:39:01Z","timestamp":1781588341000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Signal mining of adverse reactions for neuraminidase inhibitors in pregnant women: a disproportionality analysis based on the FDA adverse event reporting system database"],"prefix":"10.3389","volume":"13","author":[{"given":"Bo","family":"Cao","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Suzhou Ninth People's Hospital, Suzhou Ninth Hospital Affiliated to Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingfeng","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Suzhou Ninth People's Hospital, Suzhou Ninth Hospital Affiliated to Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenchen","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Suzhou Ninth People's Hospital, Suzhou Ninth Hospital Affiliated to Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuping","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Suzhou Ninth People's Hospital, Suzhou Ninth Hospital Affiliated to Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongjie","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Suzhou Ninth People's Hospital, Suzhou Ninth Hospital Affiliated to Soochow University","place":["Suzhou, Jiangsu, China"]},{"name":"Department of Rehabilitation, Suzhou Ninth People\u2019s Hospital, Suzhou Ninth Hospital Affiliated to Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1001\/jama.2010.479","article-title":"Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States","volume":"303","author":"Siston","year":"2010","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1093\/cid\/ciq144","article-title":"Risk factors for severe illness with 2009 pandemic influenza A (H1N1) virus infection in China","volume":"52","author":"Yu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2217\/fmb-2017-0096","article-title":"The impact of influenza virus infection in pregnancy","volume":"13","author":"Somerville","year":"2018","journal-title":"Future Microbiol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/1471-0528.14143","article-title":"Maternal influenza and birth outcomes: systematic review of comparative studies","volume":"124","author":"Fell","year":"2017","journal-title":"BJOG"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/bdr2.1445","article-title":"Outcomes of infants born to women with influenza A(H1N1)pdm09","volume":"111","author":"Newsome","year":"2019","journal-title":"Birth Defects Res"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3760\/cma.j.cn112137-20251120-03042","article-title":"Clinical practice guidelines for the treatment and prophylaxis of influenza in China (2025 edition)","volume":"106","year":"2026","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciy866","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza","volume":"68","author":"Uyeki","year":"2019","journal-title":"Clin Infect Dis"},{"key":"ref8","volume-title":"WHO Guidelines for Pharmacological Management of Pandemic Influenza A(H1N1) 2009 and Other Influenza Viruses","year":"2010"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"ofab138","DOI":"10.1093\/ofid\/ofab138","article-title":"Clinical effectiveness and safety of antivirals for influenza in pregnancy","volume":"8","author":"Chow","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"631","DOI":"10.2165\/11536370-000000000-00000","article-title":"Safety of oseltamivir in pregnancy: a review of preclinical and clinical data","volume":"33","author":"Donner","year":"2010","journal-title":"Drug Saf"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/bcp.15033","article-title":"Neonatal outcomes after neuraminidase inhibitor use during pregnancy: a meta-analysis of cohort studies","volume":"88","author":"Lian","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.drudis.2008.12.012","article-title":"Decision support methods for the detection of adverse events in post-marketing data","volume":"14","author":"Hauben","year":"2009","journal-title":"Drug Discov Today"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e0308998","DOI":"10.1371\/journal.pone.0308998","article-title":"Adverse events associated with oseltamivir and baloxavir marboxil in against influenza virus therapy: a pharmacovigilance study using the FAERS database","volume":"19","author":"Zhou","year":"2024","journal-title":"PLoS One"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/14740338.2025.2495854","article-title":"Comparative safety analysis of baloxavir marboxil and oseltamivir based on the FAERS database","volume":"25","author":"Tu","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"bbab347","DOI":"10.1093\/bib\/bbab347","article-title":"Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source","volume":"22","author":"Noguchi","year":"2021","journal-title":"Brief Bioinform"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1442002","DOI":"10.3389\/fphar.2024.1442002","article-title":"A disproportionality analysis of low molecular weight heparin in the overall population and in pregnancy women using the FDA adverse event reporting system (FAERS) database","volume":"15","author":"Xu","year":"2024","journal-title":"Front Pharmacol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1063625","DOI":"10.3389\/fphar.2022.1063625","article-title":"Potential safety signal of pregnancy loss with vascular endothelial growth factor inhibitor intraocular injection: a disproportionality analysis using the Food and Drug Administration adverse event reporting system","volume":"13","author":"Sakai","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2165\/00002018-200225060-00002","article-title":"A data mining approach for signal detection and analysis","volume":"25","author":"Bate","year":"2002","journal-title":"Drug Saf"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1002\/bdr2.1566","article-title":"Oseltamivir use in pregnancy: risk of birth defects, preterm delivery, and small for gestational age infants","volume":"111","author":"Chambers","year":"2019","journal-title":"Birth Defects Res"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"293.e1","DOI":"10.1016\/j.ajog.2013.01.015","article-title":"Infant outcomes among pregnant women who used oseltamivir for treatment of influenza during the H1N1 epidemic","volume":"208","author":"Xie","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1111\/1471-0528.12640","article-title":"Pregnancy outcome following maternal use of zanamivir or oseltamivir during the 2009 influenza A\/H1N1 pandemic: a national prospective surveillance study","volume":"121","author":"Dunstan","year":"2014","journal-title":"BJOG"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"130.e1-9","DOI":"10.1016\/j.ajog.2013.04.007","article-title":"Outcomes of infants exposed to oseltamivi or zanamivir in utero during pandemic (H1N1) 2009","volume":"209","author":"Saito","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1111\/j.1471-0528.2000.tb11621.x","article-title":"Influenza virus infection in the second and third trimesters of pregnancy: a clinical and seroepidemiological study","volume":"107","author":"Irving","year":"2000","journal-title":"BJOG"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1002\/bdr2.1563","article-title":"Oseltamivir exposure in pregnancy and the risk of specific birth defects","volume":"111","author":"Van Bennekom","year":"2019","journal-title":"Birth Defects Res"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1001\/jama.283.8.1016","article-title":"Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group","volume":"283","author":"Treanor","year":"2000","journal-title":"JAMA"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/S0140-6736(00)02288-1","article-title":"Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group","volume":"355","author":"Nicholson","year":"2000","journal-title":"Lancet"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"20499361251347726","DOI":"10.1177\/20499361251347726","article-title":"Antiviral therapy for influenza in high-risk outpatients: a multicenter observational study of routine clinical practice in Russia","volume":"12","author":"Tokin","year":"2025","journal-title":"Ther Adv Infect Dis"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1391003","DOI":"10.3389\/fphar.2024.1391003","article-title":"The real-world safety of oseltamivir and baloxavir marboxil in children: a disproportionality analysis of the FDA adverse event reporting system","volume":"15","author":"Wei","year":"2024","journal-title":"Front Pharmacol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1056\/NEJM199709253371302","article-title":"Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections","volume":"337","author":"Hayden","year":"1997","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1056\/NEJM200003023420914","article-title":"Respiratory distress associated with zanamivir","volume":"342","author":"Williamson","year":"2000","journal-title":"N Engl J Med"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"780","DOI":"10.4103\/0253-7613.103301","article-title":"Comparison of efficacy and safety of oseltamivir and zanamivir in pandemic influenza treatment","volume":"44","author":"Tuna","year":"2012","journal-title":"Indian J Pharmacol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.2165\/00002018-200124150-00003","article-title":"Zanamivir: a review of clinical safety in individuals at high risk of developing influenza-related complications","volume":"24","author":"Gravenstein","year":"2001","journal-title":"Drug Saf"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): explanation and elaboration","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1821866\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T05:39:02Z","timestamp":1781588342000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1821866\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":34,"alternative-id":["10.3389\/fmed.2026.1821866"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1821866","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"article-number":"1821866"}}